Investors in cash trouble should check out Aurinia Pharmaceuticals Inc. (AUPH)

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) stock fell -7.69% on Wednesday to $10.44 against a previous-day closing price of $11.31. With 3.73 million shares changed hands, the volume of the stock remained heavier than its average volume of 3.1 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $11.20 whereas the lowest price it dropped to was $10.39. The 52-week range on AUPH shows that it touched its highest point at $13.41 and its lowest point at $4.07 during that stretch. It currently has a 1-year price target of $16.00. Beta for the stock currently stands at 1.18.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AUPH was down-trending over the past week, with a drop of -2.52%, but this was down by -5.69% over a month. Three-month performance surged to 24.29% while six-month performance rose 125.00%. The stock lost -11.82% in the past year, while it has gained 141.67% so far this year. A look at the trailing 12-month EPS for AUPH yields -0.68 with Next year EPS estimates of -0.42. For the next quarter, that number is -0.18. This implies an EPS growth rate of 45.50% for this year and 38.20% for next year.

Float and Shares Shorts:

At present, 142.64 million AUPH shares are outstanding with a float of 132.88 million shares on hand for trading. On Apr 27, 2023, short shares totaled 16.71 million, which was 11.68% higher than short shares on Mar 30, 2023. In addition to Mr. Peter S. Greenleaf M.B.A. as the firm’s Pres, CEO & Director, Mr. Joseph M. Miller CPA serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 38.24% of AUPH’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 25.00% of AUPH, in contrast to 10.36% held by mutual funds. Shares owned by individuals account for 0.51%. As the largest shareholder in AUPH with 4.64% of the stake, BlackRock Fund Advisors holds 6,616,789 shares worth 6,616,789. A second-largest stockholder of AUPH, Armistice Capital LLC, holds 4,172,000 shares, controlling over 2.93% of the firm’s shares. SSgA Funds Management, Inc. is the third largest shareholder in AUPH, holding 2,580,012 shares or 1.81% stake. With a 2.00% stake in AUPH, the iShares Russell 2000 ETF is the largest stakeholder. A total of 2,848,070 shares are owned by the mutual fund manager. The Fidelity Small Cap Index Fund, which owns about 0.79% of AUPH stock, is the second-largest Mutual Fund holder. It holds 1,126,009 shares valued at 12.67 million. CREF Stock Account holds 0.78% of the stake in AUPH, owning 1,106,423 shares worth 12.45 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, AUPH reported revenue of $28.19M and operating income of -$35.99M. The EBITDA in the recently reported quarter was -$35.15M and diluted EPS was -$0.25.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AUPH since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With AUPH analysts setting a high price target of $15.00 and a low target of $12.00, the average target price over the next 12 months is $13.71. Based on these targets, AUPH could surge 43.68% to reach the target high and rise by 14.94% to reach the target low. Reaching the average price target will result in a growth of 31.32% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.